Anzeige
Mehr »
Samstag, 31.01.2026 - Börsentäglich über 12.000 News
Über 2 Mio. Unzen Gold - und trotzdem erst 59 Mio. USD Börsenwert?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

AUSTRALIEN 

WKN:  ISIN:  
Markt oder Branche auswählen:

Aktuelle News zu Aktien im AUSTRALIEN

  • 24 h
  • 7 Tage
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:  Alle DE EN
LeserMedien
07:10Wasseraufbereitungsspezialist De.mem vor Rekordjahr: Wendepunkt mit Rückenwind
FrAlta Copper Corp.: Alta Copper Receives Court Approval for Proposed Acquisition by Fortescue312VANCOUVER, BC / ACCESS Newswire / January 30, 2026 / Alta Copper Corp. (TSX:ATCU)(OTCQX:ATCUF)(BVL:ATCU) ("Alta Copper" or the "Company") is pleased to announce that the Supreme Court of British Columbia...
► Artikel lesen
FrWhy these brokers are very bullish on the WiseTech share price1
Frioneer Ltd - 6-K, Report of foreign issuer3
FrDeterra Royalties posts higher Q2 revenue as MAC iron ore shines1
FrEuropean Lithium-Aktie sorgt für Hochspannung: Experten sehen mögliches Momentum - SONDERMELDUNG!
FrSharon AI to deploy 1,000-strong Nvidia B200 cluster at NextDC Melbourne data center15
FrHot Chili Quarterly Report - Period Ending 31 December 20251
FrEUROPEAN LITHIUM LIMITED im Bewertungsfokus34
FrIoneer plunges after launching $50M capital raise1
FrAlpha HPA completes A$225m capital raise for Stage 2 project: Australia-listed Alpha HPA has successfully completed a fully ...2
FrIoneer launches A$72-million capital raise: Australia- and US-listed Ioneer has secured firm commitments to raise about ...-
FrQ2 FY26: Star Entertainment delivers A$6m EBITDA profit1
FrAmplia Therapuetics Limited: Amplia Therapeutics - Quarterly Activities and Cash Flow Reports - December 2025114Melbourne, Australia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Key Highlights from the Quarter ACCENT Trial Success: The ACCENT trial, testing narmafotinib with gemcitabine and Abraxane®, continues to demonstrate...
► Artikel lesen
FrIperionX - December 2025 Quarterly Report67CHARLOTTE, N.C., Jan. 30, 2026 (GLOBE NEWSWIRE) -- IperionX Limited (IperionX) (NASDAQ: IPX, ASX: IPX) is pleased to present its quarterly report for the period ending December 31, 2025. Highlights...
► Artikel lesen
FrAmerican Tungsten and Antimony: American Tungsten & Antimony Acquires Fully Permitted U.S. Tungsten Mill Securing a 'Fast-tracked' Tungsten Production Hub84NEW YORK and TOOELE COUNTY, Utah, Jan. 30, 2026 /PRNewswire/ -- American Tungsten & Antimony Ltd. (ASX: AT4; OTCQB: ATALF) announced it has executed binding agreements...
► Artikel lesen
FrKazia reports promising data for nuclear PD-L1 degrader NDL22
FrKazia Therapeutics Limited: Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)74Data identify nuclear PD-L1 as a previously unaddressed driver of immunotherapy resistance and metastatic progression SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia...
► Artikel lesen
FrALTERITY THERAPEUTICS LTD - 6-K, Report of foreign issuer2
FrSpark New Zealand Sells 75% Stake Of Data Centre Business To PEP1
Weiter >>